- Long-term data support radiofrequency ablation (RFA) as an effective treatment option in patients with small renal masses (size,
- RFA yielded good oncologic outcomes at 10 years, and no recurrence was developed after 5 years.
Why this matters
- 10-year data are consistent with the current recommendations for renal tumors
- Study of 106 patients (112 renal tumors) who underwent radiofrequency ablation during 2000-2007.
- Funding: None.
- 112 tumors were treated with radiofrequency ablation.
- Median follow-up duration was 79 months; 65 patients had ≥10 years follow-up.
- Mean tumor size was 2.5 cm.
- Mean tumor size in the recurrence group was 3.2 cm, and for patients without recurrence it was 2.4 cm (P=.005).
- At 6 years, DFS was 89%, 6-year cancer-specific survival (CSS) was 96%, and metastasis-free survival was 96%.
- At 6 years, patients with tumor size
- In 65 patients with ≥10-year follow-up, DFS, CSS, and OS were 81.5%, 94%, and 49%, respectively.
- 80% recurrences occurred in patients with tumors ≥3 cm.
- No recurrence occurred after 5 years.
- Retrospective design.